Recent SEC filings
Insider and ownership filing tracker
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
Company and financial overview
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Financial performance charts
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
Upcoming catalyst timeline
Review the Earnings tab for the expected date and estimates.
8-K
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
How the research score works
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
Company overview
Medtronic is a diversified medical technology company producing devices across cardiac and vascular therapies, diabetes management, surgical products, and neuroscience, serving hospitals and healthcare providers worldwide.
Business model
The company earns revenue from selling medical devices across a broad portfolio, with recurring consumables and service revenue tied to its large installed device base, particularly in cardiac and diabetes management categories.
Growth drivers
- New product launches across its diversified device portfolio
- Diabetes technology innovation including continuous glucose monitoring integration
- Robotic assisted surgery platform expansion
- International market growth
Competitive position
Medtronic's broad device portfolio and scale give it exposure across many medical device categories, though it has faced more competitive pressure in certain segments like diabetes technology relative to more focused competitors.
Risks
Innovation pace has lagged some competitors in specific categories in recent years, competition in robotic surgery and diabetes technology is intensifying, and healthcare capital spending cycles affect device purchasing.
Valuation
Medtronic trades at a moderate multiple relative to other large medical device companies, reflecting market expectations for a gradual reacceleration in growth as newer products scale.
Final view
Medtronic's broad device portfolio provides diversification, though it needs to demonstrate improved innovation execution to close the growth gap with faster growing device peers. My view is neutral, with new product traction being the key thing to monitor.
Overall rating: 66/100
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.